XPro1595, a second-generation TNF-α inhibitor, targeting only the soluble form of TNF-α, thus preserving the neuroprotective transmembrane TNF-α signaling pathways [354], has been evaluated in three different mouse models of AD. This evidence concerns the gene TNF and Alzheimer disease.